Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (November 2022)
48 slides from Prescient Therapeutics's shareholder meeting presentation, Nov 29, 2022
Slide 1: Progress. Positioning. Annual General Meeting
Progress. Positioning. Annual General Meeting November 2022
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on
Slide 3: Innovative pipeline in personalised medicine
Innovative pipeline in personalised medicine Platform Program Screening Preclinical Phase IB Phase II AML CD33; CLL-1 Novel TCR binder Her2+ solid Her2 tumours GBM Her2; EGFRviii Platform extensions Various CellPryme-M Cell manufacturing enhancement CellPryme-A Adjuvant for cell therapy PTX-100 TCL
Slide 4: Key achievements during another productive year
Key achievements during another productive year 4
Slide 5: Targeted Therapy Achievements
Targeted Therapy Achievements Excellent progress of PTX-100 trial Initiation and enrolment of expansion cohort in TCL • Initiation was significantly delayed by logistics bottlenecks in manufacturing and shipping drug, but good enrolment rate has made up ground Demonstrating excellent safety PT
Slide 6: Internal OmniCAR programs progressing through pre clinical development
Internal OmniCAR programs (AML; Her2+ solid tumours; GBM) progressing through pre clinical development Technical successes with various aspects of a highly novel platform Strategic collaboration with MD Anderson Cancer Center • Largest cancer centre in US • Novel TCR-like binder from proprieta
Slide 7: Developed in-house in collaboration with Peter Mac
CELL MANUFACTURING ENHANCEMENT ADJUVANT THERAPY Announced in June 2022 Announced in September 2022 Produces longer lasting, more “youthful” Overcomes hostile TME CAR-T cells Reduces Tregs Doubles helper T cells Increases expansion of CAR-T cells in vivo Doubles tumour control Doubl
Slide 8: Market backdrop
2". Prescient eee Therapeutics
Slide 9: Considerable sector headwinds
Considerable sector headwinds • Inflation hits tech and biotech companies harder, given its erosive effects on future-valued assets… • …but eventually this is counterbalanced by elasticity of demand • Geopolitical uncertainty further eroded risk appetite • Generalist (“tourist”) investors that were
Slide 10: Global Biotech valuations have stabilised
Global Biotech valuations have stabilised • Enterprise valuations* (a proxy for technology value) appear to have stabilised • Distress signal are abating (e.g. number of companies with negative EVs are decreasing) *EV = Market capitalisation – cash + debt Source: Torreya 10
Slide 11: Factors that could see US biotech sector regain traction
Factors that could see US biotech sector regain traction • Signs that clean-out from generalist investors has ended (appears to have happened) • Looking past the worst of inflation fears; stabilising rate movements • Pressure to cover short positions • Biotech fund inflows • Fund inflows remain very
Slide 12: PTX-100
PTX-100 FIRST IN CLASS RAS PATHWAY INHIBITOR 12
Slide 13: PTX-100 Phase 1B Summary
PTX-100 Phase 1B Summary Licensed from • Licensed from Yale University • Targeting cancers predisposed to Ras & Rho mutations Principal Investigator Phase 1b Expansion cohort in T-cell lymphomas (TCL) • Excellent safety profile • Encouraging signal in TCL • Reponses Professor H. Miles Prince, AM • T
Slide 14: Now in Expansion Cohort for TCL
Now in Expansion Cohort for TCL Case Study • 8 – 12 patients with r/r T cell lymphoma • pralatrexate (Folotyn®) • Approved for PTCL • Expanding number for CTCL patients in light of responses • 5,600 cases/year in US • US$450,540 per patient, per year • Potential bridge to registration study, althoug
Slide 15: Trial update: continued encouraging responses & time on treatment
Trial update: continued encouraging responses & time on treatment CLINICAL REPOSNES & MONTHS ON TREATMENT • 1 VGPR (ongoing) • 3 PRs (1 ongoing) • 2 SDs (both ongoing) • 2 PD Very Good Partial Response (VGPR) Partial Response (PR) • 3 withdrawn Stable Disease (SD) Ongoing treatment Progressive Disea
Slide 16: Before After
4. Prescient py Ra Therapeutics
Slide 17: PTX-200
PTX-200 NOVEL AKT INHIBITION 17
Slide 18: Phase 1B trial underway: Acute Myeloid Leukemia
Phase 1B trial underway: Acute Myeloid Leukemia • Building upon encouraging Phase 1 results with PTX-200 (monotherapy) Principal Investigator • PI Professor Jeff Lancet at Moffitt, Key Opinion Leader in AML • 24 patients with cytarabine held constant at 200-400 mg/m 2 as continuous infusion • 4 pati
Slide 19: Prime positioning in the cell therapy industry
Prime positioning in the cell therapy industry 19
Slide 20: CAR-T is booming
CAR-T is booming GlobalData forecasts CAR-T sales to 2028 exceed US$37bn TODAY GlobalData forecasts Kymriah® sales to exceed 2023 • 10y+ remissions US$1bn • Accelerating progress • 100s of companies targeting different antigens to target 2017 more cancer cells FDA designates CARs a "break-through” t
Slide 21: CAR-T sector continues its considerable growth despite headwinds
CAR-T sector continues its considerable growth over last 12 months despite headwinds CAR-T Programs Clinical Trials Target Antigens 2,412 800+ 220+ ↑ 80% ↑ 14% ↑ 63% Prescient Therapeutics proprietary data 21
Slide 22: Understanding antigen landscape is vital
Understanding antigen landscape is vital Heme cancers • Very crowded in certain indications • ~65% of research is on 4 antigens • Prescient has unsurpassed knowledge of the cell therapy landscape by indication & antigen • Crucial in determining competitive forces & opportunities • OmniCAR can work w
Slide 23: Platforms to overcome CAR-T's key challenges
Platforms to overcome CAR-T’s key challenges Challenge Safety / Control No control post infusion - Difficulties with targeting, Targeting antigen heterogeneity - Safe Escape Difficulties with mutating antigens - Effective Production efficiency Cost prohibitive & slow - Sustainable Exhaustion
Slide 24: Strategically positioned in the rapidly moving cell therapy landscape
Strategically positioned in the rapidly moving cell therapy landscape Autologous Allogeneic ϒδ T Cells T cells cells cells NK cells Others Targets CD19 BCMA Others Other B cell Multiple Solid Non-oncology Indications lymphomas myeloma hematological tumours diseases malignancies Transduction Lentivir
Slide 25: Prescient's CAR-T platform business model
Prescient’s CAR-T platform business model PTX Programs PTX CD33 + CLL-1 PTX platforms PTX HER2 • Huge market PTX HER2 + EGFRviii • “Shovels to CAR-T External partners goldrush” Partner 1 Partner 2 • Diversified risk Partner 3 Partner 4 • Highly scalable Partner 5 • Earlier revenue potential Partner
Slide 26: The End Game: Personalized Plug & Play
The End Game: Personalized “Plug & Play” Cell Therapy Ecosystem Step 4: Step 3: Bespoke therapy with Pair binders with OmniCAR cells post-infusion control (T cells; NK; auto/allo) Step 2: Match patient’s antigens to corresponding binders Step 1: Patient sample to determine individual antigen profile
Slide 27: Top-down analysis is sensible for investors
Top-down analysis is sensible for investors Oncology* 1 Biggest Market in • 2021: US$ 280bn Healthcare? • 2029: US$ 536bn (8.2% CAGR) 2 Fastest growing area Cell Therapies (CAR-T) in oncology? • >US$37bn by 2028^ Prescient Therapeutics 3 Forefront of • Next gen platforms Cell Therapy? • Scalable • C
Slide 28: Universal, Next Generation CAR-Therapies
Universal, Next Generation CAR-Therapies 28
Slide 29: OmniCAR: flexible, modular CAR platform
OmniCAR: flexible, modular CAR platform Targeting ligand Using any SpyTag targeting Covalent bond ligand… Spy Catcher Associate Professor Professor Daniel J. Powell, Jr Andrew Tsourkas Signalling domain …with any UNARMED ARMED CAR-T immune cell CAR-T cell cell 29
Slide 30: OmniCAR: Control Features
OmniCAR: Control Features Modular and covalent architecture of OmniCAR enables true post-infusion control of CAR functionality Dose Titration On/off switch Target Re-direction Multi-Antigen Targeting Control activity to safe Turn therapy on/off/on Re-direct cells from Target multiple cancer and effi
Slide 31: OmniCAR is at least as potent as conventional CAR-T
OmniCAR is at least as potent as conventional CAR-T Conventional CAR-T (Her2) OmniCAR (Her2) Her2+ breast cancer cell line MCF7 was co-cultured with either conventional CAR-T or OmniCAR-T cells both at 2:1 ratio Red = live cancer cells Green =dead cancer cells No Loss of Potency with modular approac
Slide 32: OmniCAR cell can be Redirected
OmniCAR cell can be Redirected Target Re-direction in Coculture of GBM Cells HER2 expressing HER2 or EGFRviii EGFRviii 1 OmniCAR T cells pre-armed with EGFRviii binder → Rapid cytotoxicity to EGFRviii+ cells 2 Add Her2 binder → Rapid switching & cytotoxicity to Her2+ cells No new cells required 100n
Slide 33: OmniCAR cells viable & armable for weeks
OmniCAR cells viable & armable for weeks OC25OC25 Mice with tumour tumours growth curves Binder administered from day 21 150 Binder administration 25ug every 2 days • Unarmed & armed OmniCAR-T cells Tumour size (mm2) 100 Untreated are viable for weeks Unarmed OmniCAR-T • Can be armed at will 50 • Re
Slide 34: Strategic collaboration with MD Anderson
Strategic collaboration with MD Anderson CD33 binder TCR-like binder CLL-1 binder • MDACC is the largest cancer centre in US OmniCAR T cell • Using “plug & play” features of OmniCAR to combine novel TCR-like binder with CD33 & CLL-1 for AML • Create best-in-class adaptable CAR-Ts for blood cancers •
Slide 35: Cell therapy enhancements
CELL THERAPY ENHANCEMENTS 35
Slide 36: The CAR-T process
The CAR-T process T-Cells are genetically altered to have Blood is collected from 1 the patient 2 T-Cells are isolated 3 cancer-recognising receptors (CARs) CAR-T cells are administered to 4 Millions of CAR-T cells are grown 5 the patient 36
Slide 37: Cell manufacturing enhancement
Cell manufacturing enhancement 37
Slide 38: More memory cells required for clinical efficacy
More memory cells required for clinical efficacy • Clinical efficacy of CAR-T therapy remains dependent on the T cell phenotype • It is possible to control this during the manufacturing step We need more of Current CAR-T makes these cells too many of these cells CXCR3 CXCR3 Naïve T cells Stem memory
Slide 39: CellPryme-M produces CAR-T cell types with ideal characteristics and attributes
CellPryme-M produces CAR-T cell types with ideal characteristics and attributes Immune memory Persistence Central memory T cells typically persist For longevity of effects and 10-20 years and as long as 75 years continued tumour control Trafficking Tumour penetrance CAR-T cells able to find their wa
Slide 40: Adjuvant for enhancing cell therapies
Adjuvant for enhancing cell therapies 40
Slide 41: CellPryme-A addresses the hostile Tumour Microenvironment (TME)
CellPryme-A addresses the hostile Tumour Microenvironment (TME) • TME is the complex ecosystem surrounding solid tumours • Protects and nurtures the cancer • Acts as a protective “force field” that bluntens the effectiveness of cancer therapies 41
Slide 42: Summary of CellPryme-A effects
Summary of CellPryme-A effects Boosts tumour killing by Improved survival conventional CAR-T cells Dramatically increases Reduces problematic CAR-T cell expansion within Treg cells by 66% • 2x ↑ CAR-T cell expansion host • 9x↑ Cytotoxic T cells with CellPryme- • 6x ↑ Helper T cells M Increases abili
Slide 43: CellPryme Complements OmniCAR
CellPryme Complements OmniCAR • Multi-targeting • Redirection • Control & safety • Any target; any cell Adjuvant therapy Process that produces • Reduces Tregs a better cell type • Primes TME for cell • Persistence therapy • Trafficking • Boosts CAR-T cell expansion in vivo Next generation Current ge
Slide 44: Summary
Summary 44
Slide 45: Key building blocks to Prescient's future value
Key building blocks to Prescient’s future value 1 2 3 Targeted therapies • Next generation universal • Enhancing current & • PTX-100 CAR platform next-gen cell therapies ▪ Exciting opportunity in ▪ AML • Manufacturing TCL ▪ Her2+ solid tumours enhancements ▪ US Orphan Drug ▪ GBM • Adjuvant therapy d
Slide 46: Major catalysts to work towards next year
Major catalysts to work towards next year Prescient will continue to progress the development of programs across its considerable pipeline. Some notable catalysts to work towards include, but are not limited to: • Read out on TCL of PTX-100 trial • Clarification of next steps for PTX-100’s clinical
Slide 47: Investment Thesis Summary
Investment Thesis Summary 4 blue chip Superior Huge & oncology assets positioning & model growing market 2 next gen platforms Internal products + external partnering $280bn industry PTX-100 & PTX-200 Shovels to goldrush Growing demand in clinic Top pedigree Highly scalable Cell therapy is the future
Slide 48: Thank you!
Thank you! ASX code: PTX www.ptxtherapeutics.com
Prescient Therapeutics — Shareholder Meeting (November 2022) on 6ix